GLOBAL VARICELLA LIVE VACCINE MARKET FORECAST 2020-2028

The global varicella live vaccine market is anticipated to grow at a CAGR of 5.78% between 2020 and 2028, and is anticipated to generate a revenue of $4.27 billion by 2028. Varicella vaccines encompass a reduced form of varicella-zoster virus. These injections help build resistance against the varicella-zoster disease, since the contamination can cause grave diseases such as herpes zoster and chickenpox.

Major factors boosting the global varicella live vaccine market growth are:

• The rise in the awareness of varicella live vaccines usage
• Active participation of government in immunization curricula
• The surge in the acceptance of varicella live vaccines

To know more about this report, request a free sample copy.

The important drivers increasing growth in the global varicella live vaccine market are the rise in the awareness of varicella live vaccines usage and surge in the acceptance of varicella live vaccines. The active government initiatives and continuous efforts in order to ensure immunization, boost the market growth of varicella live vaccines. There has been a recent increase in the adoption of varicella live vaccines worldwide. This is due to the widespread, easy availability of these vaccines.

In 2019, around 58.26% of revenue share was captured by chickenpox immunization in terms of the varicella live vaccine application. On the other hand, the herpes zoster immunization is anticipated to be the fastest-growing application. Chickenpox is a common childhood disease that occurs in all parts of the world. It is caused by the varicella-zoster virus. However, the disease can be prevented by successful immunization against it. Herpes Zoster or Shingles is a viral infection that occurs when a dormant varicella-zoster virus (VZV) reactivates from its latent state in the nerve ganglia of the previously infected individuals. The early symptoms include headache, fever, and malaise, which are followed by a sensation of burning pain, itching, hyperesthesia, or paresthesia.

The time-consuming process for the development of varicella live vaccine and huge capital expenditures are the major factors hindering the global varicella live vaccine market growth. The development of vaccines is a time-consuming process that comprises different phases. Phase I includes a study on a small group of volunteers to evaluate the safety, tolerance, and immunological effect that is displayed at different levels of doses. A rise in the mandate for various types of vaccines has been observed, and these are expected to enter into the market in the upcoming days. However, the R&D of the vaccine is a tiring process and takes a long period.

The report on the global varicella live vaccine market includes segmentation analysis on the basis of application, product, and provider.

Product is segmented into:

• Combination Varicella Vaccine
• Monovalent Varicella Vaccine

Application is segmented into:

• Herpes Zoster Immunization
• MMRV Immunization
• Chickenpox Immunization

Provider is segmented into:

• Public Provider
• Private Provider

Geographically, the global varicella live vaccine market has been segmented on the basis of four major regions, which includes:

• North America: The United States and Canada
• Europe: France, Belgium, Poland, Germany, The United Kingdom, Italy, Russia, and Rest of Europe
• Asia Pacific: South Korea, Japan, Vietnam, Australia, New Zealand, China, Thailand, Indonesia, India, and Rest of Asia Pacific
• Rest of World: Latin America, the Middle East & Africa

In 2019, North America captured the largest market share of 42.85% in terms of revenue. The varicella live vaccine market in North America is expected to hold the largest share by 2028, due to a strong focus on the varicella vaccination program. Major countries in the region include the U.S. and Canada. The factors that boost the growth of the varicella live vaccine market in North America include the easy availability of varicella live vaccine and varicella vaccine being a part of routine vaccines.

On the other hand, the Asia-Pacific market is anticipated to the fastest-growing region for the varicella live vaccine market report, due to increasing healthcare expenditure and surging availability of improved healthcare services. In addition, the growing awareness of the importance of immunization is another factor that boosts the growth of the global varicella live vaccine market in this region.

The key market players of the global varicella live vaccine market are:

• Glaxosmithkline PLC
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Novavax Inc.
• Sanofi
• Others

Key strategies adopted by some of the varicella live vaccine companies are:

In November 2019, Takeda and MD Anderson announced collaboration to accelerate the development of clinical-stage, off-the-shelf CAR NK-Cell Therapy Platform. Moreover, in February 2019, Heritage Pharma Lab Inc., a subsidiary of Emcure pharmaceutical ltd. announced acquisition of 23 FDAs approved abbreviated new drug application.

Key findings of the global varicella live vaccine market are:

• The monovalent varicella vaccine is the highest revenue-generating product.
• Herpes Zoster immunization is the fastest-growing application.
• Private providers hold the largest market share in terms of varicella vaccine providers.